反应详情

Prepared according to Example 50, using (R)-2-(2-methyl-3-(pyrrolidin-3-ylamino)quinoxalin-5-yl)-6,7-dihydro-1H-pyrrolo[3,2-c]pyridin-4(5H)-one (Ex. 61, 135 mg, 0.372 mmol), Et3N (57.0 μl, 0.410 mmol), and Ac2O (70.3 μl, 0.745 mmol) in DCM (3.7 mL). Purification by trituration with Et2O provided 2-(3-(((3R)-1-acetyl-3-pyrrolidinyl)amino)-2-methyl-5-quinoxalinyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one (72 mg, 47.8%). 1H NMR (DMSO-d6) δ: 7.84-7.91 (m, 1H), 7.57-7.62 (m, 1H), 7.32-7.40 (m, 1H), 7.12-7.21 (m, 2H), 6.91-6.98 (m, 1H), 4.61-4.75 (m, 1H), 3.45-3.98 (m, 3H), 3.38-3.45 (m, 2H), 2.82-2.90 (m, 2H), 2.57 (s, 3H), 2.04-2.44 (m, 2H), 1.98 (s, 3H), 1.12-1.21 (m, 2H). m/z (ESI, +ve) 405.1 (M−H)+.

1. customPrepared
2. customPurification by trituration with Et2O